Is DB09 Leading Towards A New First-Line Standard Of Care? – Drs. Krie, Mardones, & O’Dea

Recorded live at SABCS 2025, Amy Krie, Mabel Mardones, and Anne O’Dea break down the data that could redefine first-line treatment for HER2-positive metastatic breast cancer.

From the legacy of CLEOPATRA to the stunning DB09 results showing median PFS exceeding 40 months, this expert roundtable explores what this shift means in real-world practice.

They tackle patient selection, CNS metastases, toxicity management, dose reductions, and how using the most effective drug first is what is most ethically imperative.

🎧 A must-watch discussion on efficacy, quality of life, and how clinicians should navigate this rapidly changing HER2+ landscape.